KHI Cardiovascular Trials Project Survey for Stakeholders
KHI Cardiovascular Trials Survey
Kidney disease is highly prevalent among patients with cardiovascular disease and is associated with worse cardiovascular outcomes. Thus, the management of cardiovascular disease in patients with kidney disease is a common and important clinical problem. However, the evidence on which to base the optimal management of cardiovascular disease in patients with advanced chronic kidney disease (CKD) (i.e., estimated glomerular filtration rate <30 ml/min/1.73 m2) not requiring dialysis and end-stage renal disease (ESRD) requiring dialysis is limited by their exclusion from cardiovascular trials performed in the general population and challenges with conducting dedicated trials in these populations.
We are conducting a survey to understand the challenges with involving patients with advanced CKD not requiring dialysis and ESRD requiring dialysis in cardiovascular clinical trials and to generate solutions to overcome these challenges. We are defining cardiovascular clinical trials as studies of drugs such as (though not limited to) antiplatelet and anticoagulant agents, or heart failure treatments; procedures such as percutaneous coronary intervention; and devices such as a wearable cardioverter defibrillator.
Your responses will be anonymous. Thank you for your participation.